Day One

Wednesday January 29, 2020

Day Two

Thursday January 30, 2020

7:45 am

Coffee & Registration

8:45 am Chair’s Opening Remarks

An Update on PARP Development

9:00 am PARP & Immunotherapy

  • Geoffrey Shapiro Director Early Drug Development Center , Dana-Faber Institute

9:30 am On the Cutting-Edge of PARPi

  • Mitch Raponi Vice President, Biomarkers & Translational Research , BeiGene

10:00 am Not all PARPs are Alike: Exploring the Therapeutic Potential of PARPi Beyond PARP1 Inhibitors

  • Heike Keilhack Senior Vice President Biological Sciences, Ribon Therapeutics

10:30 am Recent progress on Replication Combing Assay (RCA) using giant DNA fibers and machine learning algorithm

10:40 am

Morning Refreshments & Speed Networking

11:35 am Deciphering the DDR genetic landscape in human tumors using patient-derived experimental models

11:45 am Over-riding PARP Resistance in Organoid & Mouse Models

12:15 pm Reversing PARP Inhibitor Resistance by Targeting the Replication Stress Response

1:00 pm

Lunch & Networking

ATR: An Emerging Target

2:00 pm Translating ATR & Emerging Targets to the Clinic

2:30 pm

Panel Discussion: The Promise of ATR & Other Emerging DDR Targets

  • Daniel Speidel Co-Managing Director , Breakpoint Therapeutics
  • Anish Thomas Investigator , National Cancer Institute
  • Ed Tian Chief Scientific Officer, IMPACT Therapeutics

3:15 pm

Afternoon Poster Session & Networking

Novel DDR Targets

4:00 pm Combination Olaparib and Ceralasertib in Homologous Repair Deficient Cancers

4:30 pm DNA-PK

  • Frank Zenke Head of DNA Damage Response Research, Merck KGaA, Darmstadt, Germany

5:00 pm Targeting protein-DNA interactions in the DDR

  • John Turchi Chief Scientific Officer, NERx Biosciences

5:30 pm Chair’s Closing Remarks

5:45 pm

End of Conference Day One